Rethinking rituximab in neuroimmunology: Real-world efficacy, cost-effectiveness, and long-term remission - PubMed
3 hours ago
- #Neuroimmunology
- #Rituximab
- #CIDP
- Rituximab (RTX) shows long-term efficacy in neuroimmunological diseases.
- A 10-year retrospective study of 40 patients in South Africa confirmed RTX's safety and cost-effectiveness compared to conventional immunotherapies.
- A case of refractory childhood-onset CIDP achieved complete and lasting remission with RTX, including functional recovery and discontinuation of other immunotherapies.
- The study advocates for earlier use of RTX in standard treatment protocols, especially in resource-limited settings.